Clinical Trial

Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

Name: Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab — clinical trial record (NCT06498622)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a multi-center, single arm study to evaluate the efficacy and safety of donafenib in combination with envafolimab treatment in patients with high risk of recurrent hepatocellular carcinoma after radical surgery.

Trial Details

NCT Number	NCT06498622
Lead Sponsor	Anhui Provincial Hospital
Conditions	Hepatocellular Carcinoma
Enrollment	45 participants
Start Date	2024-07-20
Primary Completion	2027-05-20 (estimated)
Study Completion	2027-05-20 (estimated)
Updated on ClinicalTrials.gov	2024-07-12